Genmab reaches first milestone in HuMax-TAC agreement with Serono
Genmab A/S announced it has delivered a HuMax-TAC cell line to Serono, marking the first milestone in the companies' development and commercialization agreement. The cell line could be used to manufacture HuMax-TAC for clinical trials. This milestone triggers a payment to Genmab of USD 1 Million.
In May 2005, Serono and Genmab signed an agreement under which Genmab granted Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-TAC. Under the agreement, Genmab received an upfront payment of USD 2 million and is entitled to potential milestone payments of up to USD 38 million and royalties on sales from any eventual commercialization of the product. Serono is responsible for all future development for HuMax-TAC.
HuMax-TAC is a fully human monoclonal antibody that may have therapeutic potential in the treatment of T-cell mediated diseases, such as autoimmune disorders, inflammatory and hyperproliferative skin disorders, as well as transplant rejection. HuMax-TAC is currently in pre-clinical trials.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.